Physician profile
Matthew Bartock
NPI 1700272374
$841.14
in general payments reported to CMS, 2019-2025
14 companies · $46.49 in 2025
The $46.49 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2021: $294 · 2022: $31.11 · 2023: $35.49 · 2024: $106 · 2025: $46.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $118 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $117.95 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $118.35 | 2021 | |
| Celgene Corporation | $110.56 | 2019-2023 | Pomalyst |
| Seagen INC. | $99.00 | 2021 | |
| Novo Nordisk INC | $92.87 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $88.06 | 2019 | |
| Sobi, INC | $83.51 | 2024 | |
| Janssen Biotech, INC. | $76.80 | 2021 | |
| Jazz Pharmaceuticals INC. | $75.67 | 2019 | |
| Merck Sharp & Dohme LLC | $32.91 | 2025 | Keytruda, Keytruda Qlex |
| Pharmacosmos Therapeutics INC. | $22.45 | 2024 | Monoferric |
| Pharmacyclics LLC, An Abbvie Company | $15.57 | 2023 | Imbruvica |
| Genzyme Corporation | $13.58 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.81 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bartock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.